Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Accounts Payables (2019 - 2026)

Atea Pharmaceuticals' Accounts Payables history spans 8 years, with the latest figure at $9.4 million for Q1 2026.

  • Quarterly Accounts Payables rose 27.87% to $9.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Mar 2026, up 27.87% year-over-year, with the annual reading at $12.9 million for FY2025, 190.38% up from the prior year.
  • Accounts Payables came in at $9.4 million for Q1 2026, down from $12.9 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $21.1 million in Q1 2024 to a low of $395000.0 in Q3 2023.
  • The 5-year median for Accounts Payables is $4.5 million (2024), against an average of $6.4 million.
  • Year-over-year, Accounts Payables plummeted 94.96% in 2022 and then skyrocketed 2919.57% in 2024.
  • Atea Pharmaceuticals' Accounts Payables stood at $2.6 million in 2022, then soared by 66.68% to $4.3 million in 2023, then grew by 4.84% to $4.5 million in 2024, then soared by 190.38% to $12.9 million in 2025, then decreased by 27.03% to $9.4 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Accounts Payables are $9.4 million (Q1 2026), $12.9 million (Q4 2025), and $3.5 million (Q3 2025).